{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:33:53Z","timestamp":1794641633305,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010983","name":"Health Research Fund of Central Denmark Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010983","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005940","name":"Dansk Kr\u00e6ftforsknings Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005940","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Graduate School of Health, Aarhus University, Denmark"},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with few biomarkers to inform treatment selection or patient prognosis. Methylation profiles of plasma circulating tumour DNA (ctDNA) accurately reflect tumour methylomes and may reveal novel biomarkers of mCRPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To establish a novel mCRPC-associated methylation signature for detection of ctDNA, we performed plasma methylome profiling on 27 mCRPC patients and 10 controls (cohort 1). Signature-based ctDNA detection was evaluated across prostate cancer (PC) disease stages using an internal cohort of 93 PC patients and 8 controls (cohort 2), and an external cohort of 115 PC patients (cohort 3).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We established a 48-region methylation signature (cfMeCaP) capable of highly sensitive detection of ctDNA in mCRPC (100%, 84% and 95% in cohorts 1, 2 and 3, respectively). cfMeCaP methylation at mCRPC diagnosis was associated with poor progression-free survival (PFS) and overall survival in all three cohorts (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.005), independent of routine clinical variables. Persistent serial detection of ctDNA using cfMeCaP was strongly associated with rapid mCRPC treatment failure (median PFS 4.4 vs. 65.5 months;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), while no detection predicted continued treatment response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results highlight cfMeCaP as a promising non-invasive biomarker for prognostication in mCRPC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03432-y","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T05:57:13Z","timestamp":1775800633000},"page":"127-138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Genome-wide methylome profiling of cell-free DNA enables prognostication of patients with castration-resistant prostate cancer"],"prefix":"10.1038","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0602-5981","authenticated-orcid":false,"given":"Karoline","family":"Kondrup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Iisager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8179-5989","authenticated-orcid":false,"given":"Paul Vinu","family":"Salachan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9626-6510","authenticated-orcid":false,"given":"Maibritt","family":"N\u00f8rgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3698-6241","authenticated-orcid":false,"given":"Rosalind","family":"Eeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7476-671X","authenticated-orcid":false,"given":"Torben Fr\u00f8strup","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palle J\u00f6rn Sloth","family":"Osther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Hussein","family":"Zedan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1519-9185","authenticated-orcid":false,"given":"Michael","family":"Borre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4902-5490","authenticated-orcid":false,"given":"Karina Dalsgaard","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"3432_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/bco2.116","volume":"3","author":"Y Khoshkar","year":"2021","unstructured":"Khoshkar Y, Westerberg M, Adolfsson J, Bill-Axelson A, Olsson H, Eklund M, et al. Mortality in men with castration-resistant prostate cancer\u2014A long-term follow-up of a population-based real-world cohort. BJUI Compass. 2021;3:173\u201383.","journal-title":"BJUI Compass"},{"key":"3432_CR2","doi-asserted-by":"crossref","unstructured":"Le TK, Duong QH, Baylot V, Fargette C, Baboudjian M, Colleaux L, et al. Castration-resistant prostate cancer: from uncovered resistance mechanisms to current treatments. Cancers. 2023;15:5047.","DOI":"10.3390\/cancers15205047"},{"key":"3432_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479\u201399.","journal-title":"Annu Rev Med"},{"key":"3432_CR4","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1093\/annonc\/mdv267","volume":"26","author":"K Chi","year":"2015","unstructured":"Chi K, Hotte SJ, Joshua AM, North S, Wyatt AW, Collins LL, et al. Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann Oncol. 2015;26:2044\u201356.","journal-title":"Ann Oncol"},{"key":"3432_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01508-0","volume":"20","author":"S Tian","year":"2020","unstructured":"Tian S, Lei Z, Gong Z, Sun Z, Xu D, Piao M. Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review. Cancer Cell Int. 2020;20:409.","journal-title":"Cancer Cell Int"},{"key":"3432_CR6","doi-asserted-by":"crossref","unstructured":"Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, et al. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J Natl Cancer Inst. 2017;109:djx118.","DOI":"10.1093\/jnci\/djx118"},{"key":"3432_CR7","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1038\/s41596-019-0202-2","volume":"14","author":"SY Shen","year":"2019","unstructured":"Shen SY, Burgener JM, Bratman SV, De Carvalho DD. Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA. Nat Protoc. 2019;14:2749\u201380.","journal-title":"Nat Protoc"},{"key":"3432_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41586-018-0703-0","volume":"563","author":"SY Shen","year":"2018","unstructured":"Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 2018;563:579\u201383.","journal-title":"Nature"},{"key":"3432_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34012-2","volume":"13","author":"S Chen","year":"2022","unstructured":"Chen S, Petricca J, Ye W, Guan J, Zeng Y, Cheng N, et al. The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors. Nat Commun. 2022;13:6467.","journal-title":"Nat Commun"},{"key":"3432_CR10","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","volume":"8","author":"M Annala","year":"2018","unstructured":"Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018;8:444\u201357.","journal-title":"Cancer Discov"},{"key":"3432_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-359","volume":"14","author":"R Lowe","year":"2013","unstructured":"Lowe R, Rakyan VK. Marmal-aid - a database for Infinium HumanMethylation450. BMC Bioinform. 2013;14:359.","journal-title":"BMC Bioinform"},{"key":"3432_CR12","doi-asserted-by":"publisher","first-page":"e58430","DOI":"10.7554\/eLife.58430","volume":"10","author":"E Hannon","year":"2021","unstructured":"Hannon E, Dempster EL, Mansell G, Burrage J, Bass N, Bohlken MM, et al. DNA methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia. eLife. 2021;10:e58430.","journal-title":"eLife"},{"key":"3432_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/gutjnl-2014-308859","volume":"65","author":"R Thomas","year":"2016","unstructured":"Thomas R, Lone VS, Rune T, Heidi T, S\u00f8ren V, Iver N, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. 2016;65:625.","journal-title":"Gut"},{"key":"3432_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8:1324.","journal-title":"Nat Commun"},{"key":"3432_CR15","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/bioinformatics\/btt650","volume":"30","author":"M Lienhard","year":"2014","unstructured":"Lienhard M, Grimm C, Morkel M, Herwig R, Chavez L. MEDIPS: genome-wide differential coverage analysis of sequencing data derived from DNA enrichment experiments. Bioinformatics. 2014;30:284\u20136.","journal-title":"Bioinformatics"},{"key":"3432_CR16","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/nar\/gkw1193","volume":"45","author":"M Lienhard","year":"2017","unstructured":"Lienhard M, Grasse S, Rolff J, Frese S, Schirmer U, Becker M, et al. QSEA\u2014modelling of genome-wide DNA methylation from sequencing enrichment experiments. Nucleic Acids Res. 2017;45:e44.","journal-title":"Nucleic Acids Res"},{"key":"3432_CR17","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1093\/bioinformatics\/btx183","volume":"33","author":"RG Cavalcante","year":"2017","unstructured":"Cavalcante RG, Sartor MA. annotatr: genomic regions in context. Bioinformatics. 2017;33:2381\u20133.","journal-title":"Bioinformatics"},{"key":"3432_CR18","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.18632\/oncotarget.14391","volume":"8","author":"SH Strand","year":"2017","unstructured":"Strand SH, Switnicki M, Moller M, Haldrup C, Storebjerg TM, Hedegaard J, et al. RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy. Oncotarget. 2017;8:5774\u201388.","journal-title":"Oncotarget"},{"key":"3432_CR19","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41588-020-0648-8","volume":"52","author":"SG Zhao","year":"2020","unstructured":"Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sj\u00f6str\u00f6m M, et al. The DNA methylation landscape of advanced prostate cancer. Nat Genet. 2020;52:778\u201389.","journal-title":"Nat Genet"},{"key":"3432_CR20","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1200\/JCO.2012.47.1847","volume":"31","author":"C Haldrup","year":"2013","unstructured":"Haldrup C, Mundbjerg K, Vestergaard EM, Lamy P, Wild P, Schulz WA, et al. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J Clin Oncol. 2013;31:3250\u20138.","journal-title":"J Clin Oncol"},{"key":"3432_CR21","doi-asserted-by":"publisher","first-page":"11733","DOI":"10.1073\/pnas.91.24.11733","volume":"91","author":"WH Lee","year":"1994","unstructured":"Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA. 1994;91:11733\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3432_CR22","doi-asserted-by":"publisher","first-page":"6835","DOI":"10.1038\/sj.onc.1205814","volume":"21","author":"L Liu","year":"2002","unstructured":"Liu L, Yoon J-H, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene. 2002;21:6835\u201340.","journal-title":"Oncogene"},{"key":"3432_CR23","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3390\/cells9061362","volume":"9","author":"MT Bjerre","year":"2020","unstructured":"Bjerre MT, N\u00f8rgaard M, Larsen OH, Jensen S\u00d8, Strand SH, \u00d8stergren P, et al. Epigenetic analysis of circulating tumor dna in localized and metastatic prostate cancer: evaluation of clinical biomarker potential. Cells. 2020;9:1362.","journal-title":"Cells"},{"key":"3432_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07466-6","volume":"9","author":"J Moss","year":"2018","unstructured":"Moss J, Magenheim J, Neiman D, Zemmour H, Loyfer N, Korach A, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun. 2018;9:5068.","journal-title":"Nat Commun"},{"key":"3432_CR25","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"MC Liu","year":"2020","unstructured":"Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Liu MC, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31:745\u201359.","journal-title":"Ann Oncol"},{"key":"3432_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bdq.2019.100087","volume":"17","author":"AJ Bronkhorst","year":"2019","unstructured":"Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17:100087.","journal-title":"Biomol Detect Quantif"},{"key":"3432_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.csbj.2021.12.001","volume":"20","author":"M Sharma","year":"2022","unstructured":"Sharma M, Verma RK, Kumar S, Kumar V. Computational challenges in detection of cancer using cell-free DNA methylation. Comput Struct Biotechnol J. 2022;20:26\u201339.","journal-title":"Comput Struct Biotechnol J"},{"key":"3432_CR28","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1158\/1078-0432.CCR-21-0110","volume":"27","author":"JM Burgener","year":"2021","unstructured":"Burgener JM, Zou J, Zhao Z, Zheng Y, Shen SY, Huang SH, et al. Tumor-na\u00efve multimodal profiling of circulating tumor dna in head and neck squamous cell carcinoma. Clin Cancer Res. 2021;27:4230\u201344.","journal-title":"Clin Cancer Res"},{"key":"3432_CR29","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1101\/gr.119347.110","volume":"21","author":"JH Kim","year":"2011","unstructured":"Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, Kalyana-Sundaram S, et al. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res. 2011;21:1028\u201341.","journal-title":"Genome Res"},{"key":"3432_CR30","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1158\/1078-0432.CCR-12-3139","volume":"19","author":"K Kron","year":"2013","unstructured":"Kron K, Trudel D, Pethe V, Briollais L, Fleshner N, van der Kwast T, et al. Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer. Clin Cancer Res. 2013;19:3450\u201361.","journal-title":"Clin Cancer Res"},{"key":"3432_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsbmb.2016.04.009","volume":"166","author":"CE Massie","year":"2017","unstructured":"Massie CE, Mills IG, Lynch AG. The importance of DNA methylation in prostate cancer development. J Steroid Biochem Mol Biol. 2017;166:1\u201315.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"3432_CR32","doi-asserted-by":"publisher","first-page":"169ra10","DOI":"10.1126\/scitranslmed.3005211","volume":"5","author":"MJ Aryee","year":"2013","unstructured":"Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med. 2013;5:169ra10\u2013ra10.","journal-title":"Sci Transl Med"},{"key":"3432_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45475-w","volume":"15","author":"NM Fonseca","year":"2024","unstructured":"Fonseca NM, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha AJ, et al. Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat Commun. 2024;15:1828.","journal-title":"Nat Commun"},{"key":"3432_CR34","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1158\/1078-0432.CCR-24-1096","volume":"30","author":"CJ Sweeney","year":"2024","unstructured":"Sweeney CJ, Petry R, Xu C, Childress M, He J, Fabrizio D, et al. Circulating tumor DNA assessment for treatment monitoring adds value to PSA in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2024;30:4115\u201322.","journal-title":"Clin Cancer Res"},{"key":"3432_CR35","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/clinchem\/hvac224","volume":"69","author":"M N\u00f8rgaard","year":"2023","unstructured":"N\u00f8rgaard M, Bjerre MT, Freds\u00f8e J, Vang S, Jensen JB, De Laere B, et al. Prognostic value of low-pass whole genome sequencing of circulating tumor DNA in metastatic castration-resistant prostate cancer. Clin Chem. 2023;69:386\u201398.","journal-title":"Clin Chem"},{"key":"3432_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2021.05.030","volume":"80","author":"S Sumanasuriya","year":"2021","unstructured":"Sumanasuriya S, Seed G, Parr H, Christova R, Pope L, Bertan C, et al. Elucidating prostate cancer behaviour during treatment via low-pass whole-genome sequencing of circulating tumour DNA. Eur Urol. 2021;80:243\u201353.","journal-title":"Eur Urol"},{"key":"3432_CR37","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1172\/JCI130887","volume":"130","author":"A Wu","year":"2020","unstructured":"Wu A, Cremaschi P, Wetterskog D, Conteduca V, Franceschini GM, Kleftogiannis D, et al. Genome-wide plasma DNA methylation features of metastatic prostate cancer. J Clin Investig. 2020;130:1991\u20132000.","journal-title":"J Clin Investig"},{"key":"3432_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-025-01811-5","volume":"17","author":"K Kluge","year":"2025","unstructured":"Kluge K, Lotz V, Einspieler H, Haberl D, Spielvogel C, Amereller D, et al. Imaging and outcome correlates of ctDNA methylation markers in prostate cancer: a comparative, cross-sectional [\u2076\u2078Ga]Ga-PSMA-11 PET\/CT study. Clin Epigenetics. 2025;17:36.","journal-title":"Clin Epigenetics"},{"key":"3432_CR39","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1158\/2159-8290.CD-23-0754","volume":"14","author":"GM Franceschini","year":"2024","unstructured":"Franceschini GM, Quaini O, Mizuno K, Orlando F, Ciani Y, Ku S-Y, et al. Noninvasive detection of neuroendocrine prostate cancer through targeted cell-free DNA methylation. Cancer Discov. 2024;14:424\u201345.","journal-title":"Cancer Discov"},{"key":"3432_CR40","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/nmat4997","volume":"16","author":"R-h Xu","year":"2017","unstructured":"Xu R-h, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017;16:1155\u201361.","journal-title":"Nat Mater"},{"key":"3432_CR41","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2767-9764.CRC-22-0258","volume":"2","author":"MS Frank","year":"2022","unstructured":"Frank MS, Andersen CSA, Ahlborn LB, Pallisgaard N, Bodtger U, Gehl J. Circulating Tumor DNA monitoring reveals molecular progression before radiologic progression in a real-life cohort of patients with advanced non\u2013small cell lung cancer. Cancer Res Commun. 2022;2:1174\u201387.","journal-title":"Cancer Res Commun"},{"key":"3432_CR42","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","volume":"375","author":"HI Scher","year":"2010","unstructured":"Scher HI, Beer TM, Higano CS, Anand A, Taplin M-E, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1\u20132 study. Lancet. 2010;375:1437\u201346.","journal-title":"Lancet"},{"key":"3432_CR43","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"3432_CR44","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, Bono JSD, Molina A, Logothetis CJ, Souza PD, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138\u201348.","journal-title":"N Engl J Med"},{"key":"3432_CR45","doi-asserted-by":"crossref","unstructured":"Hennigan ST, Trostel SY, Terrigino NT, Voznesensky OS, Schaefer RJ, Whitlock NC, et al. Low abundance of circulating tumor DNA in localized prostate cancer. JCO Precis Oncol. 2019;3:1\u201313.","DOI":"10.1200\/PO.19.00176"},{"key":"3432_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00770-1","volume":"12","author":"E Lau","year":"2020","unstructured":"Lau E, McCoy P, Reeves F, Chow K, Clarkson M, Kwan EM, et al. Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression. Genome Med. 2020;12:72.","journal-title":"Genome Med"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03432-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03432-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03432-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T18:02:35Z","timestamp":1781546555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03432-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7,5]]}},"alternative-id":["3432"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03432-y","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RE has received honoraria from GU-ASCO, Janssen, University of Chicago, Dana Farber Cancer Institute USA as a speaker, as well as educational honorarium from Bayer and Ipsen. RE is a member of an external expert committee to AstraZeneca UK, the Active Surveillance Movember Committee, and the SAB of Our Future Health. RE undertakes private practice as a sole trader at The Royal Marsden NHS Foundation Trust and 90 Sloane Street SW1X 9PQ and 280 Kings Road SW3 4NX, London, UK.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All research forming the basis of this study was conducted in accordance with relevant rules, regulations, and guidelines and conform to the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants prior to their donation of plasma samples for a research biobank (approved by The Central Denmark Region Committees on Health Research Ethics [jr. nr. 2000-0299], The Southern Denmark Region Committees on Health Research Ethics [S-20160029], and The Danish Data Protection Agency [jr. nr. 2013-41-2041, jr. nr. 2007-58-0010, and jr. nr. 17\/34479]). The present study was approved by the Danish National Committee on Health Research Ethics [jr. nr. 1302791 and jr. nr. 1603542], who waived the requirement for patient consent, as (1) the new analyses were considered to not pose any health risk or other significant disadvantages to the participants and (2) an expert committee was established to deal with potential (although unlikely) incidental genetic findings in this new study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}